Fairmount Funds Management LLC - 22 Jan 2026 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Reporting relationship: Director
Issuer ticker: APGE
Reported as of: 22 Jan 2026
Net transaction value: -$133,525,000
SEC form: 4
Accepted by SEC: 22 Jan 2026, 20:07:15 UTC
Prior SEC filing: 08 Dec 2025
Next SEC filing: 12 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC

Key filing fact

Fairmount Funds Management LLC filed Form 4 for Apogee Therapeutics, Inc. (APGE) on 22 Jan 2026.

Key facts

This page summarizes Fairmount Funds Management LLC's Form 4 filing for Apogee Therapeutics, Inc. (APGE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Jan 2026, 20:07.

Change

Previous filing in this sequence was filed on 08 Dec 2025.
Current net transaction value: -$133,525,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (4)

CIK 0001802528 Primary reporting owner

Fairmount Funds Management LLC

Relationship: Director
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Signature date: 22 Jan 2026

CIK 0001769651

Fairmount Healthcare Fund II L.P.

Relationship: Director
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II LP
Signature date: 22 Jan 2026

CIK 0001830177

Kiselak Tomas

Relationship: Director
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak
Signature date: 22 Jan 2026

CIK 0001663607

Harwin Peter Evan

Relationship: Director
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Peter Harwin
Signature date: 22 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APGE transaction

Common Stock

Sale

Transaction value: $133,525,000
Shares: -1,750,000
Change %: -85%
Price: $76.30
Shares after: 298,647
Date: 22 Jan 2026
Ownership: By Fairmount Healthcare Fund II LP
Footnotes: F1

APGE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 51,166
Date: 22 Jan 2026
Ownership: By Tomas Kiselak

APGE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 51,166
Date: 22 Jan 2026
Ownership: By Peter Harwin

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APGE holding Derivative

Non-Voting Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 6,743,321
Date: 22 Jan 2026
Ownership: By Fairmount Healthcare Fund II LP
Underlying class: Common Stock
Underlying amount: 6,743,321
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Footnote F2

The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%.

SEC remarks

Fairmount and Fairmount Healthcare Fund II LP may each be deemed a director by deputization of the Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of the Issuer and are also each a Managing Member of Fairmount.